Business context and reporting period
The supplied filing is IsoRay, Inc.’s Form 10-Q for the quarter ended March 31, 2014, covering its fiscal third quarter and nine months ended March 31, 2014. This does not match the request metadata naming Perspective Therapeutics, Inc. and “2013 Q3”; verify the issuer and period before relying on this summary. IsoRay reports sales of brachytherapy products, including Cesium-131 seeds and the GliaSite Radiation Therapy System.
Financial performance and position
- Revenue: Product sales were $1.13 million for the quarter, down 9% year over year, and $3.27 million for nine months, down less than 1%.
- Profitability: Quarterly gross profit was $51,000 (about 4% of sales), versus $186,000 (about 15%) a year earlier. Nine-month gross loss was $60,000 versus gross profit of $7,000. Quarterly operating loss was $989,000, compared with $824,000; nine-month operating loss was $3.27 million, versus $3.05 million.
- Net loss: $2.08 million for the quarter versus $715,000; $4.28 million for nine months versus $2.86 million. The 2014 periods included noncash warrant-liability remeasurement expense of $1.10 million for the quarter and $1.01 million for nine months. Loss per share was $0.05 for the quarter and $0.13 for nine months, versus $0.02 and $0.08, respectively.
- Cash flow: Nine-month operating cash use was $2.24 million, little changed from $2.27 million. Investing cash use was $22,000. Financing provided $23.06 million, principally from equity offerings and warrant exercises.
- Liquidity and debt: Cash and cash equivalents were $23.70 million at March 31, 2014, up from $2.90 million at June 30, 2013. Current assets were $25.11 million and current liabilities $1.02 million. The balance sheet lists no conventional borrowings; total liabilities were $2.55 million, including warrant derivative and asset-retirement liabilities.
- Equity and dilution: Common shares outstanding increased from 34.62 million at June 30, 2013 to 54.18 million at March 31, 2014. The March 2014 registered direct offering generated $13.82 million net; the August 2013 underwritten offering generated $3.28 million net. Series D preferred shares converted into common stock in January 2014.
Material changes versus comparable periods
- Quarterly sales declined, while nine-month sales were nearly flat. Prostate brachytherapy remained 82% of quarterly and 83% of nine-month product sales.
- Management cited pressure on prostate brachytherapy from competing treatments with higher reimbursement. It also noted that non-prostate applications are early-stage and sales can vary with the decisions of a small number of physicians.
- Quarterly cost of sales rose 2% despite lower sales, reducing gross margin. For nine months, cost of sales increased 2%; management cited higher isotope/material costs and the medical device tax, partly offset by lower depreciation and preloading expense.
- Quarterly general and administrative expense rose 14%, including higher bad-debt expense. Nine-month general and administrative expense rose 8%, with higher bad-debt, legal, and public-company costs. Nine-month research and development expense rose 6%, mainly due to protocol spending.
- The substantial increase in cash resulted primarily from equity issuance and warrant exercises, not operating cash generation.
Outlook, risks, contingencies, and unusual items
- Management estimated cash and cash equivalents of approximately $23.62 million at April 30, 2014 and said they should fund operations and capital needs for several years, assuming revenue and expenses remain at current levels. This is management’s estimate, not a guarantee.
- Management planned continued and new clinical protocols, including lung and intracranial applications, and estimated approximately $180,000 of fiscal 2014 protocol expense. It identified revenue growth, GliaSite sales, broader clinical applications, and cost control as paths toward breakeven; it provided no specific revenue or earnings guidance.
- Risks include persistent operating losses, weak or declining sales, competition and reimbursement pressure, limited sources for certain materials, potential future dilutive financing, and uncertainty in adoption of newer applications. The company said additional financing might be dilutive and may not be available on acceptable terms.
- A disputed know-how royalty claim with the Lawrence Family Trust remains unresolved; the parties may demand binding arbitration. The company also disclosed environmental and radioactive-material decommissioning obligations, product-liability exposure (with insurance), and no off-balance-sheet arrangements.
- The warrant derivative liability increased to $678,000 from $104,000 at June 30, 2013. Its fair-value changes materially affected reported earnings but were noncash. Management said disclosure controls were effective; it was continuing remediation of a material weakness identified in its prior-year Form 10-K.
Important facts for investors to verify
- Confirm the filing identity and reporting period: the supplied document is IsoRay’s March 31, 2014 Form 10-Q, not a Perspective Therapeutics 2013 Q3 filing.
- Review subsequent cash use and sales performance against management’s “several years” liquidity estimate, which assumes revenue and expenses remain at current levels.
- Track gross margins, isotope and material costs, medical device tax effects, and the company’s ability to grow non-prostate and GliaSite sales.
- Assess the impact of equity offerings and warrant exercises on share count, remaining warrant overhang, and potential future dilution.
- Check developments in the royalty dispute, environmental obligations, and remediation of the previously reported material weakness.